‘Founded in 2013, BioAscent is a leading provider of integrated drug discovery services based at the former Organon / Merck Sharpe and Dohme (MSD) R&D site in Newhouse, Scotland. Our drug discovery services include de novo assay development, target analysis and bespoke screening strategies, compound screening (including HTS with our 125k diversity library, fragment screening and virtual screening), medicinal chemistry, synthetic chemistry, computational chemistry and full compound management services. Our team of expert scientists has experience of successfully working from assay development through to preclinical and clinical candidates across all biological target classes and major therapeutic indications. As part of its compound management service, BioAscent currently holds and manages over 2 million compounds for customers ranging from the smallest virtual biotech to big pharma. Since 2013, the BioAscent team has been responsible for: 100+ biochemical, biophysical and cellular assays for drug discovery projects, 50+ hit validation/characterisation projects, 30+ hit-to-lead campaigns 100,000+ screening plates delivered to our global customers/partners. BioAscent is the fastest-growing drug discovery CRO in the UK, having topped the outsourcing category in the Alantra Pharma Fast 50 for the past two years running.’
